Clinical Trials Directory

Trials / Unknown

UnknownNCT03638206

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
73 (estimated)
Sponsor
Shenzhen BinDeBio Ltd. · Industry
Sex
All
Age
4 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

Detailed description

The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include ten different tumor-specific antibody.They are as following:anti-CD19 antibody for B cell leukemia and lymphoma;anti-CD22 antibody for B cell leukemia and lymphoma;anti-CD33 antibody for myeloid leukemia;anti-BCMA antibody for multiple myeloma;anti-CD38 antibody for multiple myeloma;anti-NY-ESO-1 antibody for multiple myeloma,esophagus cancer,lung cancer,melanoma and synovial sarcoma;anti-DR5 antibody for hepatoma;anti-C-met antibody for hepatoma,colorectal cancer,ovarian cancer and renal carcinoma;anti-EGFR V III antibody for hepatoma,lung cancer and glioma;anti-Mesothelin antibody for gastric cancer,pancreatic cancer and mesothelioma.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCAR-T cell immunotherapyAccording to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.

Timeline

Start date
2018-03-01
Primary completion
2023-03-01
Completion
2023-03-01
First posted
2018-08-20
Last updated
2019-12-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03638206. Inclusion in this directory is not an endorsement.